Skip to main content
Account

Table 1 Characterization of nanoparticles

From: Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy

Group

Size (nm)

Polydispersion

Zeta potential (mV)

Loading efficiency (%)

Gene

Polymer

 

(n= 3)

 

(n= 3)

(n= 3)

  

ANP

72.11 ± 3.44

0.164

22.54 ± 3.47

83.4 ± 2.3

TRAIL

PEI

BNP

71.82 ± 5.18

0.156

21.58 ± 4.16

82.6 ± 1.9

Endostatin

PEI

CNP

83.02 ± 2.35

0.178

24.65 ± 2.78

78.3 ± 3.8

TRAIL/endostatin

PEI

DNP

215.06 ± 3.52

0.186

−18.25 ± 2.36

0

None

TPGS-b-(PCL-ran-PGA)

ENP

236.31 ± 1.44

0.201

23.65 ± 3.65

0

None

PEI/TPGS-b-(PCL-ran-PGA)

FNP

265.48 ± 4.40

0.229

19.45 ± 1.99

67.4 ± 4.3

TRAIL

PEI/TPGS-b-(PCL-ran-PGA)

GNP

245.48 ± 6.42

0.215

18.45 ± 2.67

64.6 ± 3.1

Endostatin

PEI/TPGS-b-(PCL-ran-PGA)

HNP

272.97 ± 4.68

0.245

16.54 ± 1.06

62.5 ± 0.9

TRAIL/endostatin

PEI/TPGS-b-(PCL-ran-PGA)

Navigation